Oracle Named A Leader By Everest Group In Report On Clinical Development Platforms

The life sciences industry is recognizing the importance of end-to-end platforms for improving the efficiency of clinical trials.

Everest Group, a strategic research firm specializing in information technology, business processes, and engineering services, has released a new report on clinical development platforms. “In recent years, the industry has pivoted from questioning the existence of end-to-end platforms to creating a near-term vision for adopting such platforms,” the firm notes in an overview of the market.

“A unified clinical development platform with improved data architecture and analytics capabilities can accelerate the drug development process and enrich the experience for sponsors, patients, and physicians.”

Among firms providing clinical development platforms, Oracle is at the front of the pack.

Global assessment: Oracle unsurpassed

Everest Group’s “Clinical Development Platforms Products PEAK Matrix® Assessment 2022” report examined nearly two dozen clinical development platform vendors from around the world.

The assessment looked at capabilities and characteristics that influence successful outcomes.

Everest Group named Oracle a Leader in the industry.

“It’s gratifying to see this independent assessment from a noted research firm,” says Henry McNamara, senior vice president and general manager for Oracle Health Sciences.

“This appraisal not only echoes what we’re hearing from our customers and partners, but it aligns with our strategic mission – to provide a flexible, open technology platform that allows life sciences organizations to unify operations and accelerate clinical trials.”

Access the complete Everest Group report here: Clinical Development Platforms Products PEAK Matrix® Assessment 2022.

Unifying people, processes, and data

Oracle’s flagship Clinical One platform helps life sciences firms simplify and accelerate clinical trials by unifying people, processes, and data.

The Clinical One platform enables universal connectivity, effectively ingesting any data source, format, frequency, and volume associated with an application target. This allows organizations to integrate with legacy systems and a wider application ecosystem.

With the advent of decentralized clinical trials accelerated by the COVID-19 pandemic, Clinical One offers the flexibility to configure and scale for traditional, hybrid, or decentralized trials, while supporting the full range of patient choices.

“With integrated solutions encompassing trial design, site management, patient safety, and more, we’re intent on being a trusted partner for life sciences firms as they accelerate their digital transformations,” says McNamara.

Advancing and expanding

As the industry leader, Oracle is committed to pursuing new advances to stay abreast of scientific breakthroughs, regulatory change, technological advances, and the market forces that affect clinical research.

“We continue to aggressively expand and strengthen capabilities across the clinical trials spectrum, from advancing machine learning and artificial intelligence, to incorporating real-world data, and unlocking sophisticated new solutions through our acquisition of Cerner,” says McNamara. “Our partners, and ultimately patients, depend on it.”

For more information, visit Oracle Clinical One.

Michael McCann, Global Vice President Sales, Alliances and Channels

Michael McCann has over 30 years of experience in enterprise technology across life sciences domains including drug discovery, clinical development, regulatory and commercial. He has been the global sales leader for Oracle's Health Sciences group since its October 2020. Prior to that he led the Americas Health Sciences sales organization since the business unit’s inception in 2008.

As the global sales leader, Michael is responsible for the growth of clinical development and pharmacovigilance solutions relied upon by biotech, pharma, medical device, and CRO customers. Prior to Oracle he was part of the life sciences group at Siebel Systems, VP of Sales at Active Strategy, VP of Sales at EMAX Solutions, Sales VP at Computer Associates, and software engineer at Unisys Corporation.

Michael McCann holds a Bachelor of Arts degree in Computer Science and Finance from LaSalle University and an MBA in International Business from the LeBow College of Business at Drexel University.